Background: Polycystic ovary syndrome (PCOS) is one of the most common endo-
| INTRODUC TI ON
Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder among reproductive-aged women. Depending on the diagnostic criteria used and the population studied, its prevalence PCOS ranges between 9 and 18% 1 with a higher prevalence among women who are overweight 2 or of an Indigenous background. 3, 4 The Rotterdam Consensus (2003) is the most widely accepted diagnostic criteria for PCOS and requires the presence of at least two of the following characteristics: (a) clinical and/or biochemical hyperandrogenism, (b) oligo-/anovulation or (c) polycystic ovaries on ultrasound, with exclusion of secondary causes of hyperandrogenism. 5 The recently developed international evidence-based guideline for the assessment and management of PCOS 6 has refined the Rotterdam criteria in adolescence to hyperandrogenism and oligo-/anovulation and recommended against ultrasound due to poor specificity of polycystic ovaries in this age group. While the aetiology of PCOS remains unclear, it is likely to be multifactorial. Insulin resistance (IR) and hyperandrogenism are the two key hormonal disturbances that underpin PCOS, with obesity, genetic inheritance, lifestyle and environment also contributing to the multifactorial aetiology of PCOS. 7, 8 Women with PCOS may present with a number of reproductive, 9 metabolic, 10,11 psychological 12 and anthropometric 13 complications.
The most common PCOS feature is ovarian dysfunction driven by hyperandrogenism which leads to chronic oligo-/anovulation and menstrual disturbances.
14 Hyperandrogenism also causes dermatological complaints such as hirsutism, 9 acne and male pattern alopecia. 15, 16 PCOS is the most common cause of anovulatory infertility, but infertility is not necessarily impaired in all affected women.
14 However, those who do become pregnant are at an increased risk of pregnancy and foetal complications regardless of the mode of conception. 17, 18 PCOS has metabolic implications including IR, 19 dyslipidaemia 20, 21 and abnormal glucose metabolism. 22, 23 Moreover, women with PCOS also show a propensity for excess weight gain which exacerbates these symptoms. 24 Cardiovascular risk factors such as chronic inflammation, oxidative stress 25 and impaired fibrinolysis are increased 24 with some evidence of a higher prevalence of cardiovascular disease (CVD). 11, 26 Furthermore, affected women are more likely to experience moderate-to-severe depression and anxiety symptoms, 27 low self-esteem, negative body image and psychosexual function compared to healthy women. 28 PCOS also negatively impacts health-related quality of life (HRQoL) 29, 30 and may limit a woman's ability to optimize healthy lifestyle.
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PCOS is a multisystem, polygenic and multifactorial disorder. It has diverse implications that can change throughout a woman's life.
It is imperative that the information available to clinicians and researchers is evidence based and generated by high-quality research studies. A systematic review is widely considered to provide the highest level of evidence compared to other study methodologies, 32 and recent years have seen an increasing number summarizing the assessment of PCOS. However, many of these reviews present conflicting results, highlighting the need for synthesis and critical appraisal of the pertaining literature to reach more consistent conclusions. The aim of this review was therefore to conduct an overview of systematic reviews evaluating comorbidities and complications of PCOS and to appraise their quality and synthesize the results. We also aimed to explore alignment between the evidence and recent evidence-based guidelines in PCOS adopted across 37 international societies.
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2 | ME THODS
| Protocol and registration
This review was designed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. 33 An a priori study protocol was registered with PROSPERO (CRD42016052649). Ethics application was not required.
| Literature search
The electronic databases MEDLINE in-process and other non- Additional ongoing reviews were identified from searching the international prospective register of systematic reviews PROSPERO (http://www.crd.york.ac.uk/PROSPERO/). The literature search was last updated on 15 September 2017. The search terms used included "PCOS," "polycystic ovary syndrome," "Stein Leventhal," "systematic," "review" and "meta-analysis" with the complete search strategy for each database provided in Appendix S1 (Supporting Information).
The search strategy was limited to human studies only.
| Eligibility criteria and study collection
Articles were included if they met the following inclusion criteria:
(a) article was an original systematic review or meta-analysis; (b)
PCOS was the primary focus of the review and if PCOS was assessed as a secondary condition as part of a broader topic the article was excluded; (c) a clear search strategy was reported with at least keywords or terms included, documentation of search returns and some form of quality appraisal of the included studies performed; (d) the study was published in English; and (e) the study was published from year 2009 onwards given this was when the PRISMA statement was published to guide reporting of systematic reviews and meta-analyses.
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For this particular review, articles assessing the comorbidities and complications associated with PCOS were included for analysis. 
| Study selection and data extraction
Identified articles from the literature search were screened in a twostep process. First, the titles and abstracts were screened for suitability. Second, all articles that appeared to meet the inclusion criteria from the first step were retrieved for detailed full-text assessment to 
| Quality assessment (AMSTAR)
The Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool was employed to appraise the quality of the included systematic reviews. 34 AMSTAR evaluates the methodological aspects of systematic reviews using 11 items. These are (a) the provision of an a priori design; (b) duplication of study selection and data 
| Data synthesis
Results of included reviews were presented in tabular format organized according to morbidity category. Statistically significant outcomes of interest were presented if a meta-analysis was performed by the review. Otherwise, a narrative description of the findings was given.
| RE SULTS

| Literature search
In total, 1068 reviews were identified for screening. Following removal of duplicates, review of title and abstract and full-text evaluation, 23 studies were included for this overview of systematic reviews. The PRISMA flow diagram is illustrated in Figure 1 .
The list of excluded articles is available in Appendix S2 (Supporting Information).
| Study characteristics
The study characteristics and PICO framework of the included systematic reviews are summarized in Table 1 . The country of origin of the authors included China (n = 5), 18, 26, 30, 35, 36 USA (n = 4), 23, [37] [38] [39] United Kingdom (UK) (n = 4), 27, [40] [41] [42] Australia (n = 4), 2, 23, 41, 43 Iran (n = 4), 19, 29, 44, 45 Greece (n = 2), 17, 46 the Netherlands (n = 2), 11, 42 Sweden (n = 1) 30 and Switzerland (n = 1).
47 N = 9 reviews included all study types. 2, 18, 27, 38, 40, [42] [43] [44] 48 N = 5 reviews included observational studies only 11, 17, 19, 41, 46 ; n = 2 included cohort and case-control studies only 26, 47 ; and n = 2 reviews explicitly included cross-sectional studies only. 37,49 N = 1 review included cohort, case-control or cross-sectional studies 45 and n = 1 included peer-reviewed primary articles. 39 N = 3 reviews did not state an inclusion criteria for the study type. 23, 29, 35 N = 12 reviews did not set a language restriction in their literature search. 11, 17, 18, 23, 26, 27, 37, 40, 42, [44] [45] [46] N = 7 reviews restricted their search to English publications only. 2, 19, 29, 35, 38, 39, 43 N = 2 reviews restricted their language to English and Chinese 30, 49 and n = 1 reviews restricted its language to English and French. 47 N = 1 reviews did not state if any language restriction was applied.
41 N = 9 reviews reported following a guideline on good practice in conducting systematic reviews 11, 18, 19, 29, 37, 39, 40, 46, 47 ; n = 22 systematic reviews included meta-analyses 2, 11, [17] [18] [19] 23, 26, 27, 29, 30, 35, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] 49 ; and n = 10 did not provide a clear statement as to the overall quality of TA B L E 2 Results of systematic reviews regarding reproductive comorbidities of PCOS TA B L E 3 Results of systematic reviews regarding metabolic comorbidities of PCOS
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and the total participants ranged from 213 to 767 988. N = 8 of the systematic reviews had 10 studies or fewer in total. 
| Methodological quality of systematic reviews
The AMSTAR scores of the included reviews are available in Appendix S3. None of the included reviews were of high quality, 21
(91%) reviews 2,11,17-19,23,26,27,29,30,37-46,49 scoring moderate quality and 2 (9%) reviews scoring low quality. 35, 47 The most commonly unreported items were potential for conflict of interest of the included studies (n = 22, 96%) and presence of priori study design (n = 22, 96%).
Other commonly unreported items were a list of included and excluded studies (n = 19, 83%) and whether duplicate study and data extraction were used (n = 19, 83%), inclusion of grey literature (n = 15, 65%) and formulation of study conclusion based on the scientific quality of the included studies (n = 15, 65%). Conducting a comprehensive literature search was reported in just under half of the reviews (n = 11, 48%), likelihood of publication bias was considered and tested in (n=17, 74%) reviews and studies were combined using appropriate methods in all but two reviews (n = 21, 91%). All systematic reviews reported the study characteristic of the included studies.
| Reproductive comorbidities of PCOS
N = 2 moderate quality reviews evaluated reproductive comorbidities of PCOS 17, 18 (Table 2) . A total of 56 papers and 115 412 adult women were included.
| Pregnancy, foetal and neonatal complications
Both reviews assessed maternal and/or foetal complications in pregnant women with PCOS. 17,18 N = 1 review reported an increased prevalence of hypoglycaemia, perinatal death, gestational diabetes (GDM), preeclampsia, pregnancy-induced hypertension (PIH), preterm delivery, caesarean delivery and miscarriage among women with PCOS.
18 N = 1 review solely evaluated the risk of GDM in women with PCOS and similarly found women with PCOS to be at a significantly higher risk of GDM compared to women without PCOS. 
| Metabolic comorbidities of PCOS
N = 14 reviews evaluated metabolic comorbidities of PCOS (Table 3) . 
| CVD and cardiovascular risk factors
CVD and associated risk factors of PCOS were assessed by n = 10 reviews. 11,18,26,35,36,38,39,41,43,46 N = 9 reviews were rated moderate 
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TA B L E 4 Results of systematic reviews regarding psychological comorbidities of PCOS quality and n = 1 was rated low quality. N = 2 reviews (n = 1 in adult women 43 and n = 1 in adolescent women 35 ) assessed the effects of and significantly lower high-density lipoprotein cholesterol (HDL-C) levels 43 and obese adolescent women with PCOS had significantly higher TC and LDL-C and significantly lower HDL-C levels. 35 Subgroup analysis in the adolescent study reported significantly higher LDL-cholesterol levels for obese adolescents with PCOS compared to BMI-matched adolescents without PCOS. reported women with PCOS were at a significantly increased risk for higher carotid intima-media thickness (CIMT) 39 and compromised flow-mediated dilatation (FMD). 41 N = 2 reviews assessed the prevalence of CVD and reported women with PCOS were at a significantly increased risk for coronary heart disease (CHD) 11, 26 and stroke. 
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| Diabetes and markers of insulin resistance
Glucose homeostasis-related PCOS outcomes were evaluated by n = 8 reviews, all of which were moderate quality. 18, 19, 23, 35, 36, 38, 43, 46 Of these reviews, n = 3 assessed the effects of obesity on glucose homeostasis in adult and adolescent women with PCOS. 19, 35, 43 For all three reviews, compared with normal weight women with PCOS, overweight and obese adult and adolescent women with PCOS had significantly greater IR. Further subgroup analyses by one review reported that being overweight or obese significantly increased fasting insulin and fasting blood glucose compared to normal weight women with PCOS and being obese compared to overweight significantly worsened fasting insulin, fasting blood glucose and IR. 
| Metabolic syndrome and nonalcoholic fatty liver disease (NAFLD)
The prevalence of metabolic syndrome was assessed by n = 2 reviews. 23, 36 One review reported women with PCOS to have increased prevalence of metabolic syndrome for BMI and non-BMI-matched women without PCOS. 23 The other review assessed the effects of HA on the incidence of MS for women with PCOS and reported a significant higher incidence for women with PCOS and HA compared to women with PCOS without HA. 49 N = 1 review assessed the risk of NAFLD in women with PCOS and reported risk was significantly higher in women with PCOS compared to women without PCOS. spect to thyroid function in women with PCOS. 46 The presence of subclinical hypothyroidism did not significantly influence BMI, waist circumference or waist-to-hip ratio.
| Psychological comorbidities of PCOS
N = 6 reviews evaluated the psychological complications of PCOS 27, 29, 37, 42, 47, 48 (Table 4 ). The reviews were of moderate quality (n = 5) and low quality (n = 1). A total of 74 studies and 9985 adult participants were involved. 
| Depression and anxiety
N = 3 reviews assessed the prevalence of symptoms of depression or anxiety in women with PCOS. 27, 37, 42 In all the reviews, meta-analysis revealed significantly higher depressive and anxiety symptom scores in women with PCOS compared to women without.
| Other morbidities
There were three reviews that we could not classify as either reproductive, metabolic or psychological categories 38, 40, 45 (Table 5) .
The reviews were all of moderate quality. A total of 50 studies and 50 906 adult women were involved.
| Cancers
The risk of cancers in women with PCOS was assessed by n = 2 reviews. N = 1 review reported across their lifespan, and women with PCOS are at increased risk of developing endometrial but not breast or ovarian cancer compared with non-PCOS controls. 40 When only women under the age of 54 were included from the analysis, this further increased the risk of endometrial cancer. Shobeiri and Jenabi 45 found no significant association between PCOS and breast cancer. 
| Vitamin
| D ISCUSS I ON
The aim of this review was to summarize existing systematic reviews and meta-analyses evaluating comorbidities and complications of PCOS. Despite a large number of reviews (n = 23) that included 575 studies and over a million participants (1 090 072), there is a lack of high-quality systematic reviews or meta-analyses. We also aimed to align evidence synthesis with the recent evidence-based guideline on PCOS, an international collaboration across 37 societies. 17, 18 which is line with the current evidence-based guidelines 6 and specialty society position statements. [55] [56] [57] [58] [59] However, these links should be interpreted with caution owing to the limited number of systematic reviews, their diverse quality and significant betweenstudy heterogeneity including study size and different diagnostic criteria.
We also report that women with PCOS had a lower quality of life, 29, 30, 42, 47 and an increased prevalence of depressive 27, 42 and anxiety symptoms 37 47 or the nature of living with a chronic disease.
The new international guideline in PCOS 6 recognizes the PCOSrelated psychological issues and emphasizes screening, assessment and management.
Two systematic reviews assessed the prevalence of obesity in women with PCOS 2,46 and reported a greater risk of obesity, 2 which was not altered by subclinical hypothyroidism status. 46 The international guideline in PCOS 6 recommends that BMI be assessed in all women with PCOS and that prevention of excess weight gain is vital. Weight loss is recommended for overweight or obese women and should be first-line treatment. 55, 56, [58] [59] [60] 62, 63 This is crucial given the recognition in both prior research and this current review of the key role of excess weight in worsening reproductive, metabolic and psychological outcomes in PCOS.
Two systematic reviews found a significant increase in risk of endometrial cancer in women with PCOS. 40, 45 This may be the result of endometrial proliferation underlined by IR and oligomenorrhea, 67 prolonged endometrial exposure to unopposed oestrogen in anovulation 68 and/or related risk factors such as obesity 69 and T2DM. There are several strengths of this study. Our search strategy was comprehensive, incorporated multiple databases and conducted in duplicate to reduce potential for random errors and bias. We note this overview of systematic reviews has some limitations. First, we restricted reviews to those published from 2009 onwards; the year the PRISMA statement was released, 33 which may exclude significant earlier studies assessing the comorbidities associated with PCOS, albeit potentially of lower quality. We also excluded non-English publications, thus potentially introducing a language bias. We also purposefully excluded reviews that focused on surrogate markers of unknown significance, for example, inflammatory cytokines and sex hormones and selected only reviews that clearly focused on PCOS comorbidities and complications that are more directly relevant to clinicians and patient care. We report the quality of the included systematic reviews were generally moderate with limitations in quality related to lacking a priori protocol driven approach or interpretation of the quality of individual studies. However, we
note that performing quality assessment of each of the more than 500 included studies would be impractical. Quality of future systematic reviews may be strengthened by addressing issues including reporting conflict of interest of included studies, registering for a priori protocol, providing a list of excluded studies, and offering greater transparency to whether or not duplicate study and data extraction were used. Our findings also aligned with recent recommendations from the international evidence-based guidelines in PCOS.
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We report for the first time a comprehensive summary and quality assessment of systematic reviews assessing comorbidities and complications in women with PCOS. We confirm that PCOS has a range of reproductive, metabolic, psychological and other manifestations. We report many of the assessed outcomes were worsened by excess adiposity, highlighting the importance of weight management as first-line PCOS therapy. We draw attention to the shortage of systematic reviews regarding pregnancy outcomes of PCOS and significant knowledge gaps in the association between NAFLD, vitamin D levels and cancers with PCOS warranting future studies to elucidate the potential pathogenic associations. It is therefore imperative that clinicians are aware of the broad spectrum of complications and comorbidities associated with PCOS and rely only on the best available evidence to maximize the effectiveness of PCOS diagnosis, treatment and management.
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